Trials / Conditions / Diffuse Hemispheric Glioma, H3 G34-Mutant

Diffuse Hemispheric Glioma, H3 G34-Mutant

7 registered clinical trials studyying Diffuse Hemispheric Glioma, H3 G34-Mutant — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of 177Lu-PSMA-617 in People With Gliomas NCT07223034	Memorial Sloan Kettering Cancer Center	Phase 1
Enrolling By Invitation	Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma NCT06896110	Andrew P. Groves	Phase 1
Withdrawn	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Re NCT05457959	Jonsson Comprehensive Cancer Center	Phase 1
Recruiting	5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours NCT06630260	Institute of Cancer Research, United Kingdom	Phase 1 / Phase 2
Recruiting	5G-EMERALD: Amivantamab in Malignant Brain Tumours NCT06632236	Institute of Cancer Research, United Kingdom	Phase 1
Recruiting	Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253	Nationwide Children's Hospital	Phase 2
Active Not Recruiting	A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma NCT06342908	Jonsson Comprehensive Cancer Center	Phase 1